Home > Boards > US Listed > Biotechs > Gamida Cell Ltd. (GMDA)

Gamida Cell to Present Full Data from Phase

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 120
Posts 25,368
Boards Moderated 8
Alias Born 02/07/04
160x600 placeholder
Gamida Cell to Present at the 20th Annual Needham Virtual Healthcare Conference Business Wire - 4/7/2021 8:00:00 AM
Gamida Cell Presents Efficacy & Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at th... Business Wire - 3/15/2021 10:24:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 3/11/2021 4:36:22 PM
Prospectus Filed Pursuant to Rule 424(b)(7) (424b7) Edgar (US Regulatory) - 3/11/2021 4:02:23 PM
Amended Annual and Transition Report (foreign Private Issuer) (20-f/a) Edgar (US Regulatory) - 3/11/2021 3:34:31 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 3/11/2021 6:04:18 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/9/2021 4:09:39 PM
Gamida clibs 5.6% despite a Q4 miss, provides 2021 guidance Seeking Alpha - 3/9/2021 11:22:41 AM
Gamida Cell EPS misses by $0.35; outlook Seeking Alpha - 3/9/2021 7:05:01 AM
Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update Business Wire - 3/9/2021 7:00:00 AM
Gamida Cell to Present at Upcoming Investor Conferences Business Wire - 3/3/2021 7:00:00 AM
Gamida Cell Announces the Date of Its Full Year 2020 Financial Results and Webcast Business Wire - 3/2/2021 7:00:00 AM
Securities Registration (foreign Private Issuer) (f-3) Edgar (US Regulatory) - 3/1/2021 4:40:43 PM
Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Soc... Business Wire - 3/1/2021 7:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/26/2021 3:13:08 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/17/2021 3:11:52 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/16/2021 2:22:05 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/16/2021 8:58:20 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 8:30:16 AM
Gamida Cell launches $75M financing with Highbridge Capital Management Seeking Alpha - 2/16/2021 8:04:19 AM
Gamida Cell Announces $75 Million Financing with Highbridge Capital Management Business Wire - 2/16/2021 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 5:53:48 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 4:46:15 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/12/2021 3:13:10 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/10/2021 4:02:17 PM
midastouch017   Tuesday, 01/12/21 01:30:43 AM
Re: None
Post # of 299 
Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR

https://finance.yahoo.com/news/gamida-cell-present-full-data-200000742.html

Mon, January 11, 2021, 10:00 PM GMT+2
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the full results of the Phase 3 clinical trial of omidubicel will be presented for the first time at the TCT Meetings, the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and Center for International Blood & Marrow Transplant Research (CIBMTR), which is being held virtually from February 8–12, 2021.

The international, multi-center, randomized Phase 3 study for omidubicel evaluated the safety and efficacy of omidubicel in patients with hematologic malignancies undergoing allogeneic bone marrow transplant compared to a comparator group of patients who received a standard umbilical cord blood transplant.

This will be the first presentation of the full efficacy and safety results of this study. Gamida Cell previously reported in 2020 top-line data for omidubicel, an advanced cell therapy under development as a potentially life-saving allogeneic hematopoietic stem cell transplant solution for patients with hematologic malignancies. Last May, Gamida Cell reported that the study achieved its primary endpoint, demonstrating a highly statistically significant reduction in time to neutrophil engraftment, a key milestone in a patient’s recovery from a bone marrow transplant. Last October, the company reported that the omidubicel phase 3 study achieved its secondary endpoints of platelet engraftment, infections, and hospitalizations.

Details about the presentation are as follows:
Title: Improved Clinical Outcomes with Omidubicel Versus Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase III Randomized, Multicenter Study
Lead Author: Mitchell E. Horwitz, M.D.
Time: Tuesday, February 9, 2021, 4:45-5:00 p.m. EST

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences